Table 2. Baseline characteristics and clinical course of 23 newly diagnosed IPF patients.

Patients, number	Gender	Age (years)	Diagnosis	Stage of fibrosis (GAP score)	Type to the outcome	Outcome itself
1	F	65	IPF	I	Slow progression	Died
2	F	76	IPF	II	Slow progression	Died, CVI
3	M	69	IPF	III	Slow progression	Died, CVI
4	M	50	IPF	I	Slow progression	Alive, dementia
5	F	68	IPF	II	Slow progression	Died
6	M	87	IPF	II	Fast progression	Died
7	F	66	IPF	I	Slow progression	Alive, stable disease
8	M	73	IPF/Ca	II	Slow progression	Died, Ac. exacerbation
9	F	68	IPF	II	Slow progression	Alive
10	M	63	IPF	II	Fast progression	Alive
11	F	56	IPF	I	Slow progression	Alive
12	F	69	IPF	II	Slow progression	Alive, stable disease
13	F	69	IPF	I	Slow progression	Alive, stable disease
14	F	58	IPF	I	Slow progression	Alive, stable disease
15	F	62	IPF	II	Slow progression	Alive, stable disease
16	M	60	IPF	I	Slow progression	Alive, stable disease
17	F	60	IPF	I	Slow progression	Alive, stable disease
18	F	80	IPF	I	Slow progression	Alive, stable disease
19	F	54	IPF	I	Fast progression	Alive
20	F	42	IPF	II	Fast progression	Died, Ac. exacerbation
21	F	83	IPF	II	Slow progression	Alive
22	F	85	IPF	II	Slow progression	Alive, stable disease
23	M	69	IPF	III	Slow progression	Alive, stable disease

IPF, idiopathic pulmonary fibrosis; Ca, cancer; Ac., acute; CVI, cerebrovascular insult.